Phase I study of GSK461364, a specific and competitive Polo-like kinase 1 inhibitor, in patients with advanced solid malignancies - Olmos, D; Barker, D; Sharma, R; Brunetto, A T; Yap, T A; Taegtmeyer, A B; Barriuso, J; Medani, H; Degenhardt, Y Y; Allred, A J; Smith, D A; Murray, S C; Lampkin, T A; Dar, M M; Wilson, R; de Bono, J S; Blagden, S P (Clin Cancer Res, 2011)